Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$34.00
▲(7.77% Upside)
Action:ReiteratedDate:04/15/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and negative equity). Technicals are a relative positive with strong upward trend, but momentum appears stretched. Valuation provides little support due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Proprietary protein synthesis platform
Sutro’s cell-free XpressCF platform is a durable technical moat: it speeds protein design, enables precise payload conjugation and supports novel ADC formats. That capability reduces development cycle time, lowers technical risk for partners, and underpins sustained R&D productivity and deal interest over quarters.
Negative Factors
Negative stockholders' equity
Negative equity reflects cumulative losses that have eroded the balance-sheet cushion, increasing dependence on external capital. This structural weakness limits borrowing capacity, raises counterparty concerns, and makes future financing likelier to be dilutive or costly, affecting long-term flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary protein synthesis platform
Sutro’s cell-free XpressCF platform is a durable technical moat: it speeds protein design, enables precise payload conjugation and supports novel ADC formats. That capability reduces development cycle time, lowers technical risk for partners, and underpins sustained R&D productivity and deal interest over quarters.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$552.19M
Dividend YieldN/A
Average Volume (3M)987.85K
Price to Earnings (P/E)―
Beta (1Y)3.44
Revenue Growth65.18%
EPS Growth24.78%
CountryUS
Employees269
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.29
Shares Outstanding16,567,238
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$35.17Price Target Upside11.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-9.55
Revenue Forecast (FY)$32.95M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specif...
How the Company Makes Money
Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
35
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -97.63M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | |||||
| Total Assets | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | |||||
| Free Cash Flow | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Positive
31.55
Price Trends
22.22
Positive
16.83
Positive
12.86
Positive
Market Momentum
2.15
Negative
75.09
Negative
87.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Positive. The current price of 31.55 is above the 20-day moving average (MA) of 25.55, above the 50-day MA of 22.22, and above the 200-day MA of 12.86, indicating a bullish trend. The MACD of 2.15 indicates Negative momentum. The RSI at 75.09 is Negative, neither overbought nor oversold. The STOCH value of 87.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $36.95M | -0.90 | -171.01% | ― | 257.14% | 9.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $552.19M | -0.53 | 275.30% | ― | 65.18% | 24.78% | |
48 Neutral | $75.81M | -0.50 | -82.96% | ― | ― | 15.32% | |
44 Neutral | $35.92M | -2.65 | -96.04% | ― | -58.86% | -47.17% | |
44 Neutral | $39.51M | -0.48 | -158.81% | ― | -100.00% | 17.96% |
* Healthcare Sector Average
STRO
Sutro Biopharma
34.69
25.94
296.59%
CRVO
CervoMed
3.71
-5.67
-60.45%
ACET
Adicet Bio
7.67
-2.29
-22.95%
INMB
Inmune Bio
1.40
-6.45
-82.17%
HOWL
Werewolf Therapeutics
0.74
-0.10
-11.90%
Sutro Biopharma Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sutro Biopharma Ends ATM Agreement After 2025 Results
Positive
Mar 23, 2026
On March 23, 2026, Sutro Biopharma reported full-year 2025 results and announced the mutual termination of its at-the-market equity sales agreement with Jefferies, closing a potential source of incremental share issuance. The company highlighted p...
Business Operations and StrategyPrivate Placements and Financing
Sutro Biopharma Highlights ADC Platform in New Presentation
Positive
Feb 10, 2026
On February 9, 2026, Sutro Biopharma entered an underwriting agreement with Leerink Partners and TD Securities to sell 7,868,383 shares of common stock at $13.98 per share, a public offering expected to generate about $110 million in gross proceed...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.